Compounded Semaglutide Side Effects: What's Normal, What's Not

Key takeaways

• The expected side effects are gastrointestinal: in the Wegovy trials, nausea affected 44% of people on 2.4 mg versus 16% on placebo, vomiting 24% versus 6%, constipation 24% versus 11%. They cluster after each dose increase and fade; 6.8% stopped because of them versus 3.2% on placebo.
• The serious warnings are rare but specific: pancreatitis, gallbladder disease, kidney injury from dehydration, low blood sugar with insulin or sulfonylureas, worsening diabetic eye disease, allergic reactions, and aspiration under anesthesia. The boxed warning on thyroid C-cell tumors comes from rodents.
• Compounded vials add risks the brand does not have: overdoses of 5 to 20 times the intended dose when units and milliliters are confused, potency and sterility nobody verifies, salt forms, and untested additives.
• Seek care the same day for severe or persistent abdominal pain, vomiting that stops you keeping fluids down, fainting, a racing heart at rest, swelling of the face or throat, or any dosing error.
• Clinicians monitor weight, blood pressure, heart rate, hydration, mood, and in people with diabetes, glucose and the eyes.

The short answer

The side effects of compounded semaglutide are the side effects of semaglutide, plus the side effects of a vial. In the brand trials, nausea, diarrhea, vomiting and constipation were common, mostly mild to moderate, worst after each dose increase, and faded with time; pancreatitis, gallbladder disease, dehydration-related kidney injury and hypoglycemia in people on insulin were rare. The vial adds dosing errors, unverified potency and untested additives. This page gives the numbers; the compounded semaglutide hub covers the product, the price and the law, and the semaglutide dosage chart covers the units arithmetic that prevents the worst of what follows.

Side effects by frequency: semaglutide 2.4 mg versus placebo

Source: Wegovy label, Table 3 (Wegovy label). In the same trials, 6.8% of people on semaglutide and 3.2% on placebo stopped because of side effects, led by nausea, vomiting and diarrhea. Severe gastrointestinal reactions occurred in 4.1% versus 0.9%, and the label advises against use in severe gastroparesis.

What the first weeks feel like, and how it is managed

Semaglutide slows stomach emptying and reduces appetite, and the gastrointestinal effects are that mechanism felt from the inside. In STEP 1, nausea and diarrhea were "typically transient and mild-to-moderate in severity and subsided with time," and 4.5% of participants stopped because of gastrointestinal events versus 0.8% on placebo (Wilding 2021). Most people describe a few days of queasiness, early fullness and burping after each dose increase, easing before the next step.

The label's management tool is the schedule itself: 0.25 mg for four weeks before any treatment dose, four-week steps thereafter, and permission to delay a step by four weeks if it is not tolerated. Within that frame, clinicians usually advise smaller meals, stopping at the first sign of fullness, and less fat and fried food, which sit longest in a slowed stomach; steady fluids through the day, because vomiting, diarrhea and reduced thirst are how semaglutide dehydrates people, and dehydration is how it injures kidneys; a short course of an anti-nausea medication from the prescriber if a step is otherwise unmanageable, rather than a self-chosen lower dose; and fiber and fluids for constipation, which, unlike nausea, tends to persist.

What is not normal in the first weeks is pain. Nausea is expected; persistent or severe abdominal pain is not, and is the symptom the label attaches to pancreatitis.

The serious warnings

These come from the Wegovy label and apply to the molecule, whoever makes it (Wegovy label).

Thyroid C-cell tumors (boxed warning). Semaglutide caused thyroid C-cell tumors in rodents at clinically relevant exposures; whether it does so in humans is unknown. It is contraindicated with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. A neck lump, trouble swallowing or persistent hoarseness should be evaluated.

Acute pancreatitis. Confirmed in 4 of the 2.4 mg patients in the weight-loss trials versus 1 on placebo (0.2 versus under 0.1 cases per 100 patient-years). Persistent severe abdominal pain, sometimes radiating to the back, means stop and seek care.

Gallbladder disease. Gallstones in 1.6% versus 0.7% and cholecystitis in 0.6% versus 0.2%, an excess that persisted after accounting for the weight lost. Pain under the right ribs with fever or yellowing of the eyes needs same-day assessment.

Hypoglycemia. In people with type 2 diabetes, clinically significant low blood sugar occurred in 6.2% versus 2.5%, and the risk rises sharply with insulin or a sulfonylurea, whose doses the label says to consider reducing when semaglutide starts. In people without diabetes serious hypoglycemia was rare (3 versus 1 events in the 17,000-patient cardiovascular trial), with a higher rate after bariatric surgery.

Acute kidney injury. Reported after marketing, some cases needing dialysis, mostly in people dehydrated by vomiting or diarrhea; in the trials, 7 patients versus 4. The label says to monitor kidney function in anyone with symptoms that could cause volume depletion.

Diabetic retinopathy complications. In a two-year trial in type 2 diabetes, retinopathy complications occurred in 3% on semaglutide versus 1.8% on placebo, and in 8.2% versus 5.2% of those who already had retinopathy; rapid glucose improvement can temporarily worsen the disease, so people with diabetes should have their retinas checked.

Mood and suicidal ideation. The label carried a warning on suicidal behavior and ideation until February 2026, when FDA removed it after its reviews found no evidence of a causal link. Asking about mood remains routine, particularly in people with a history of depression, and new or worsening low mood or thoughts of self-harm should be reported immediately.

Aspiration under anesthesia. Rare reports of stomach contents being inhaled during surgery or sedation in GLP-1 users who had fasted as instructed. Tell any anesthesia team you take semaglutide.

Also on the label: serious allergic reactions including anaphylaxis and angioedema; a resting heart rate increase averaging 1 to 4 beats per minute, with a sustained rise being a reason to stop; and the instruction to stop at least two months before a planned pregnancy because of the drug's long half-life.

The risks that belong to compounded versions

Dosing errors in units. A pen delivers a fixed milligram dose; a vial delivers whatever volume you draw. On July 26, 2024, FDA warned that patients had taken 5 to 20 times the intended dose of compounded semaglutide, with vomiting, dehydration, fainting, pancreatitis and gallstones among the results, and some hospitalized. The pattern was consistent: a patient told to draw 5 units (0.05 mL) on a 1 mL insulin syringe drew 50; a prescriber wrote 25 units when 5 was intended and the patient vomited for days; another wrote 20 instead of 2, and three patients fell ill; a health professional miscalculated her own dose tenfold (FDA dosing-error alert 2024). A poison-center series described two 10-fold self-dosing errors, one by a patient given a vial and syringes with no pharmacist counseling (Lambson 2023). In a 2026 case report, a woman injected 2 mg instead of a 0.2 mg first dose, developed swelling of the lips, tongue and throat within four hours, and spent four days on a ventilator (Kraft 2026). The arithmetic that prevents this is in the dosage chart: units equal milligrams divided by the vial's mg/mL concentration, times 100.

Salt forms. FDA has said that semaglutide sodium and semaglutide acetate, used by some compounders, are different active ingredients from the base semaglutide in the approved drugs, have not been shown to be safe or effective, and have no legal basis in compounding (FDA GLP-1 page). A legitimate label says semaglutide, not a salt.

Unverified potency and sterility. No regulator tests a 503A pharmacy's vial before it ships. In an analysis of FDA's adverse-event database from 2018 to 2024, the 707 reports involving compounded GLP-1 products had far higher odds of preparation errors, contamination and manufacturing problems than reports involving the approved products, higher odds of abdominal pain, nausea, diarrhea, gallbladder inflammation and suicidality, and more than twice the odds of hospitalization. Reporting is voluntary, so these are signals, not rates (McCall 2026).

The FDA reports. By May 31, 2026, FDA had received 990 adverse-event reports involving compounded semaglutide and more than 730 involving compounded tirzepatide. A report does not prove the product caused the event, and FDA says the totals are probably undercounts because many state-licensed pharmacies are not required to report (Drug Discovery and Development 2026).

When to seek care

Call your prescriber the same day, or go to an emergency department, for:

• severe or persistent abdominal pain, especially radiating to the back, or pain under the right ribs with fever;
• vomiting or diarrhea that stops you keeping fluids down for more than a day, dizziness on standing, or very little urine;
• fainting, a heart racing at rest, or swelling of the face, lips, tongue or throat;
• confusion, shakiness or sweating that suggests low blood sugar, particularly on insulin or a sulfonylurea;
• sudden vision changes in a person with diabetes, or a neck lump, hoarseness or trouble swallowing that does not resolve;
• new or worsening low mood or thoughts of self-harm;
• any suspected dosing error, even without symptoms, because the drug lasts a week and symptoms can start hours later.

Poison Control (1-800-222-1222) handles dosing errors around the clock and will want the units drawn and the concentration on the vial.

What clinicians monitor

A program that is treating you rather than shipping to you checks, at baseline and at each dose step: weight and blood pressure; resting heart rate; hydration and kidney function after vomiting or diarrhea; blood glucose in anyone with diabetes, with insulin or sulfonylurea doses adjusted; retinal examinations in people with diabetes; mood; gallbladder and pancreatic symptoms; and, for a compounded product, the concentration on the vial against the units on your instructions. The label itself asks for glucose monitoring in diabetes, kidney monitoring with volume-depleting symptoms, retinopathy monitoring, and heart-rate checks at regular intervals.

Bottom line

Normal is nausea, burping, loose stools or constipation in the days after a dose increase, fading before the next one. Not normal is pain, dehydration, fainting, swelling, or a dose that was five times what the chart said. The first list is the molecule, documented in 2,116 trial patients; the second is where the compounded product's own record lives, in FDA's alert, a poison center's case series and nearly a thousand reports that nobody has to file. Know your concentration, know your units, and call early.

Frequently asked questions

+−Is compounded semaglutide safe?

The molecule has a large safety record from the brand trials, in which the most common problems were nausea, diarrhea, vomiting and constipation, and about 7% of people stopped because of side effects. The compounded product adds risks the brand does not have: overdoses of 5 to 20 times the intended dose from unit and milliliter confusion, potency and sterility that no regulator checks, salt forms, and additives such as B12 that were never studied with it. FDA had logged 990 adverse-event reports involving compounded semaglutide by May 31, 2026 and says that is probably an undercount.

+−Does semaglutide cause hair loss?

The Wegovy label lists hair loss in 3% of people on 2.4 mg versus 1% on placebo, more often in women (4% versus 0.9% in men), and attributes it to the weight loss itself rather than the drug. Shedding that follows rapid weight loss is usually temporary and regrows over months; a clinician will check iron, thyroid and protein intake if it persists.

+−How do I relieve nausea from semaglutide?

Nausea is most common in the weeks after each dose increase and usually fades. The label's tool is time: if a step is not tolerated, the prescriber can hold the dose for another four weeks before increasing it. Smaller meals, less fat and fried food, stopping eating when full, and steady fluids help most people; a prescriber can add an anti-nausea medication for a short period. Vomiting that stops you keeping fluids down is a reason to call, because dehydration is how semaglutide injures kidneys.

+−How long do semaglutide side effects last?

In the STEP 1 trial nausea and diarrhea were mostly mild to moderate, transient, and subsided with time, typically within days to a few weeks of each dose step. Because the drug has a half-life of about a week, a side effect from a single high dose can last a week or more, which is why an overdose from a vial is not a one-day problem.

+−What are the signs of pancreatitis on semaglutide?

Persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea and vomiting. The label says to stop semaglutide and seek care if pancreatitis is suspected. It was rare in the trials, 4 confirmed cases among the 2.4 mg patients versus 1 on placebo, but it is the warning most often confused with ordinary stomach upset.

+−Can semaglutide cause low blood sugar if I do not have diabetes?

Rarely. In the 17,000-patient cardiovascular trial of people without diabetes there were 3 serious hypoglycemia events on semaglutide versus 1 on placebo, with a higher rate in people who had bariatric surgery. The real hypoglycemia risk is in people with diabetes who take insulin or a sulfonylurea, whose doses usually need reducing when semaglutide starts.

+−What should I do if I injected too much compounded semaglutide?

Call Poison Control (1-800-222-1222) or your prescriber right away, even if you feel fine, and say how many units you drew and the concentration on your vial. Overdoses have caused severe vomiting, dehydration, fainting, pancreatitis, gallstones and low blood sugar, and because the drug lasts a week the symptoms can go on for days. Go to an emergency department for repeated vomiting, severe abdominal pain, fainting, or swelling of the face, lips or throat.

+−Does semaglutide cause suicidal thoughts?

The Wegovy label carried a warning about suicidal behavior and ideation from its approval until February 2026, when FDA removed it after its reviews found no evidence that the drug causes them. Clinicians still ask about mood at follow-up, especially in people with a history of depression, and an analysis of FDA adverse-event reports found suicidality reported more often with compounded GLP-1 products than with the brands, a signal that may reflect who takes them and how they are monitored rather than the molecule.

Sources

1. LabelNovo Nordisk. Wegovy (semaglutide) injection and tablets: prescribing information, revised June 2026 (DailyMed setid ee06186f-2aa3-4990-a760-757579d8f77b). (2026)
2. StudyWilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002. (2021)
3. RegulatoryFDA. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. July 26, 2024 (examples as summarized by Patient Care Online, July 30, 2024). (2024)
4. StudyLambson JE et al. Administration errors of compounded semaglutide reported to a poison control center: case series. J Am Pharm Assoc 2023;63:1643-5. (2023)
5. StudyKraft BD et al. Angioedema after accidental semaglutide dosing error: a case report. J Clin Med 2026;15. (2026)
6. StudyMcCall KL et al. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA Adverse Event Reporting System. Expert Opin Drug Saf 2026;25. (2026)
7. RegulatoryFDA. FDA's concerns with unapproved GLP-1 drugs used for weight loss (compounding after the shortages, salt forms, adverse event reports; content current as of October 1, 2026).
8. NewsBuntz B. FDA logs more than 1,700 adverse event reports involving compounded semaglutide and tirzepatide (990 and 730 as of May 31, 2026). Drug Discovery and Development, August 24, 2026. (2026)